Publication:
Circulating hTERT mRNA as a tumor marker in cholangiocarcinoma patients

dc.contributor.authorKawin Leelawaten_US
dc.contributor.authorSurang Leelawaten_US
dc.contributor.authorThawee Ratanachu-Eken_US
dc.contributor.authorSomboon Trubwongchareonen_US
dc.contributor.authorJerasak Wannapraserten_US
dc.contributor.authorSaad Tripongkarunaen_US
dc.contributor.authorSuchart Chantawibulen_US
dc.contributor.authorPanadda Tepaksornen_US
dc.contributor.otherRajavithi Hospitalen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherRangsit Universityen_US
dc.contributor.otherNational Institutes of Health, Bethesdaen_US
dc.date.accessioned2018-08-20T07:14:50Z
dc.date.available2018-08-20T07:14:50Z
dc.date.issued2006-07-14en_US
dc.description.abstractAim: To investigate human telomerase reverse transcriptase (hTERT) mRNA in the serum of cholangiocarcinoma patients. Methods: The serum of thirty three cholangiocarcinoma patients, forty one benign biliary tract disease patients and ten healthy volunteers were collected and analyzed for the expression of hTERT mRNA by real-time reverse transcriptase-polymerase chain reaction (RT-PCR). We then examined the correlation between values of serum hTERT mRNA and the pathological staging of cholangiocarcinoma. Results: hTERT mRNA was detected in 28 of 33 (84.85%) of serum obtained from cholangiocarcinoma patients and 9 of 41 (21.9%) of serum obtained from benign biliary tract disease patients. hTERT mRNA was not detected in any serum obtained from healthy volunteers. on the other hand the common tumor marker, CA19-9 was detected in 20 of 33 (60.6%) of serum obtained from cholangiocarcinoma patients and 8 of 41 (19.5%) of serum obtained from benign biliary tract disease patients. However, no correlation was found between the present of serum hTERT mRNA and tumor staging. Conclusion: These results indicate that the detection of circulating hTERT mRNA was identified in almost all cholangiocarcinoma patients. It offers a novel tumor marker, which can be used as a complementary study for diagnosis of cholangiocarcinoma. © 2006 The WJG Press. All rights reserved.en_US
dc.identifier.citationWorld Journal of Gastroenterology. Vol.12, No.26 (2006), 4195-4198en_US
dc.identifier.doi10.3748/wjg.v12.i26.4195en_US
dc.identifier.issn10079327en_US
dc.identifier.other2-s2.0-33748605027en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/23696
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=33748605027&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleCirculating hTERT mRNA as a tumor marker in cholangiocarcinoma patientsen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=33748605027&origin=inwarden_US

Files

Collections